The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia

References

• Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study. Lancet 2012;380(9859):2129-43
   PubMed Web of Science ®Google Scholar
• Schultz SK, Andreasen NC. Schizophrenia. Lancet 353(9162):1425-30
   Google Scholar
• Kapur S. Looking for a "biological test" to diagnose "schizophrenia": are we chasing red herrings? World Psychiatry 2011;10(1):32
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. The diagnostic and statistical manual of mental disorders. DSM-5. 5th edition. American Psychiatric Association; 2013
   Google Scholar
• Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet.10 2014;383(9929):1677-87
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012;5:CD008016
   PubMed Web of Science ®Google Scholar
• Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013;70(10):1107-12
   PubMed Web of Science ®Google Scholar
• Keith S, Kane JM. Partial Compliance and patient consequences in schizophrenia: Our patients can do better. J Clin Psych 2003;64:1308-15
   Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 2013;66(8 Suppl):S37-41
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication non adherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 2009;70(7):990-6
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. EUFEST study group: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Mullins CD, Obeidat NA, Cuffel BJ, et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res 2008;98:8-15
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatric Clin North Am 2007;30:437-52
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. Expert consensus panel on adherence problems in serious and persistent mental illness. the expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl 4):1-46
   PubMed Web of Science ®Google Scholar
• Haddad P, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v oral antipsychotics in schizophrenia: systematic review of randomized controlled trials and observational studies. Br J Psychiatry 2009;195:s20-8
   Web of Science ®Google Scholar
• Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl 2009;52:S1-4
   PubMedGoogle Scholar
• Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 2007;68(Suppl 14):27-30
   PubMed Web of Science ®Google Scholar
• Alphs L, Schooler N, Lauriello J. How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophrenia. Schizophr Res 2014;156(2-3):228-32
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Krystal JH, Lew R, et al. CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011;364(9):842-51
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomized long-term trials. Schizophr Res 2011;127(1-3):83-92
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Koen L, et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008;30:2378-86
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-17
   PubMed Web of Science ®Google Scholar
• Macfadden W, Ma YW, Thomas H J, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry 2010;7:23-31
   PubMedGoogle Scholar
• Weiden P J, Schooler N R, Weedon J C, et al. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. J Clin Psychiatry 2012;73:1224-33
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review Schizophr. Res Treat 2012;40:70-1
   Google Scholar
• Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 2013;28:57-66
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Niatt M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957-65
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014;40:192-213
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Dean J, Carter V, et al. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin 2014;30(8):1643-55
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013;74(6):568-75
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:e290-9
   PubMed Web of Science ®Google Scholar
• Kane JM, Meltzer HY, Carson WHJr, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68(2):213-23
   PubMed Web of Science ®Google Scholar
• Kane JM, Crandall DT, Marcus RN, et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007;95(1-3):143-50
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009;65(6):510-17
   PubMed Web of Science ®Google Scholar
• Kern RS, Green MF, Cornblatt BA. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187(3):312-20
   PubMed Web of Science ®Google Scholar
• Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009;70(4):572-81
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168(9):947-56
   PubMed Web of Science ®Google Scholar
• Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007;22(7):433-43
   PubMed Web of Science ®Google Scholar
• Han M, Huang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol 2009;12(7):941-52
   PubMed Web of Science ®Google Scholar
• Cheng MC, Liao DL, Hsiung CA, et al. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol 2008;11:207-16
   PubMed Web of Science ®Google Scholar
• Yang TT, Wang SJ. Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse 2008;62:804-18
   PubMed Web of Science ®Google Scholar
• Segnitz N, Schmitt A, Gebicke-Härter P, Zink M. Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. Neurochem Int 2009;55:619-28
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44(2):179-87
   PubMed Web of Science ®Google Scholar
• Abilify® (aripiprazole) tablets: US prescribing information. Prescriber’s information. Available from: www.otsuka-us.com/Documents/Abilify.PI.pdf [Last accessed 21 October 2014]
   Google Scholar
• Cutler AJ, Marcus RN, Hardy SA, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006;11(9):691-702
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71
   PubMed Web of Science ®Google Scholar
• Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry 2007;68(5):662-8
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Daniel DG, Carson WHJr, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007;41(11):895-905
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64(9):1048-56
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009;65(6):510-17
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
   PubMed Web of Science ®Google Scholar
• Kane JM, Crandall DT, Marcus RN, et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007;95(1-3):143-50
   PubMed Web of Science ®Google Scholar
• Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22(6):363-70
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-36
   PubMed Web of Science ®Google Scholar
• Kane JM, Barnes TR, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol 2010;24(7):1019-29
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123(2-3):225-33
   PubMed Web of Science ®Google Scholar
• Stroup TS, Byerly MJ, Nasrallah HA, et al. Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 2013;146(1-3):190-5
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Suttajit S, Maneeton N. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res 2015;62:38-47
   PubMed Web of Science ®Google Scholar
• Wanga L J, Reea S C, Huangb Y S, et al. Adjunctive effects of aripiprazole on metabolic profiles: Comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013;40:260-6
   PubMed Web of Science ®Google Scholar
• Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev 2011;8:CD006622
   PubMed Web of Science ®Google Scholar
• Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr 2004;9(10 Suppl 11):6-14
   PubMed Web of Science ®Google Scholar
• Abilify maintena: product monograph. Available from: //www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Abilify_Maintena_Feb_2014/Abilify_Maintena.pdf [Last accessed 04 April 2015]
   Google Scholar
• US FDA. ABILIFY MAINTENA™ (aripiprazole) for extended-release injectable suspension, for intramuscular use: prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2013/202971s000lbl.pdf [Last accessed 29 October 2014]
   Google Scholar
• European Medicines Agency. Abilify Maintena: summary of product characteristics. Available from: www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/002755/human_med_001711.jsp&mid=WC0b01ac058001d124 [Last accessed 24 October 2014]
   Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res 2013;150(1):281-8
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73(5):617-24
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomised non-inferiority study. Br J Psychiatry 2014;205:A7
   Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(Suppl 44):11-19
   Google Scholar
• Barnes TR. A Rating Scale for Drug-Induced Akathisia. British Journal of Psychiatry 1989;154:672-6
   PubMed Web of Science ®Google Scholar
• Strickland TP, Baker RA, McQuade R, et al. Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: a 52-week open-label study. Poster presented at the American Psychiatry Association Meeting; 3 – 7 May 2014, New York
   Google Scholar
• Fleischhacker WW, Baker RA, Eramo A, et al. Peters-Strickland T,. Effects of aripiprazole once-monthly on domains of personal and social performance: Results from 2 multicenter, randomized, double-blind studies. Schizophr Res 2014;159(2-3):415-20
   PubMed Web of Science ®Google Scholar
• Karow A, Moritz S, Lambert M, et al. Egofors initiative. remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry 2012;27(6):401-5
   PubMed Web of Science ®Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014;75(11):1254-60
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-13
   PubMed Web of Science ®Google Scholar
• Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ 2013;16(7):917-25
   PubMedGoogle Scholar
• Kane JM, Zhao C, Johnson B. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ 2015;18(2):145-54
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Sanchez R, Johnson B. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol 2013;28(4):171-6
   PubMed Web of Science ®Google Scholar
• Potkin SG, Raoufinia A, Mallikaarjun S, et al. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin 2013;29(10):1241-51
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005;6(12):2091-101
   PubMed Web of Science ®Google Scholar
• Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010;16(5):488-501
   PubMed Web of Science ®Google Scholar
• Gary R, Foussias G. The neurobiology of relapse in schizophrenia. Schizophrenia Research 2014;152(2-3):381-90
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Alvir JM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996;14(3 Suppl):13S-21S
   PubMed Web of Science ®Google Scholar
• Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs 2013;27(8):637-52
   PubMed Web of Science ®Google Scholar